StonvexLoading…
StonvexStonvexStonvexCore line items from ALGN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $1.04B | $4.03B | $2.99B | $1.99B |
Operating Income | $141.96M | $545.75M | $390.43M | $294.13M |
Net Income | $112.77M | $410.35M | $274.59M | $217.84M |
EPS (Diluted) | $1.57 | $5.65 | $3.77 | $2.98 |
Total Assets | $6.31B | $6.23B | $6.23B | $6.22B |
Total Liabilities | $2.16B | $2.18B | $2.28B | $2.31B |
Cash & Equivalents | $1.06B | $1.09B | $1.00B | $901.16M |
Free Cash Flow OCF − CapEx | $120.26M | $490.78M | $303.52M | $134.56M |
Shares Outstanding | 71.62M | 71.36M | 72.04M | 72.49M |